HEXO Corp. (HEXO)
(Delayed Data from AMEX)
$7.73 USD
+0.27 (3.62%)
Updated May 3, 2019 04:00 PM ET
After-Market: $7.72 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[HEXO]
Reports for Purchase
Showing records 1 - 20 ( 137 total )
Industry: Medical - Products
U.S. Cannabis Industry: 1Q23 Takeaways and Outlook
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Industry: Medical - Products
Weekly ReHash: Price Deflation a Needed Market Dynamic to Convert Illicit Mkt
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Industry: Medical - Products
Weekly ReHash: Toronto Securities Exchange an Open Pathway for MSO Lisitngs
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Industry: Medical - Products
Weekly ReHash: Pricing is Key to Improving Industry Fundamentals
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Industry: Medical - Products
Industry: Medical - Products
Weekly ReHash: Early Readthrough Into 1Q22 Confirms Industry Headwinds
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Industry: Medical - Products
Industry: Medical - Products
Industry: Medical - Products
Weekly ReHash: Israel - Pioneering Cannabis into a Large Market Opportunity
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Industry: Medical - Products
Industry: Medical - Products
Weekly ReHash: Cannabis SPACs Underperformed in 2021, Reset
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Industry: Medical - Products
Industry: Medical - Products
Industry: Medical - Products
Weekly ReHash: CAOA Feedback, Fall Potential Legislation Passage In Budget Bill
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Industry: Medical - Products
Industry: Medical - Products
Weekly ReHash: Ranking 2Q Earnings Reports, Well Capitalized MSOs
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Industry: Medical - Products
A Day of Progress for Cannabis Legislative Reform
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Industry: Medical - Products
Expectations of Schumer''s Legalization Plan
Provider: Roth Capital Partners, Inc.
Analyst: Research Department